Boston Scientific Shares Slide on Cautious 2026 Revenue Forecast

Medical device maker's acquisition of Penumbra overshadows strong Q4 results.

Published on Feb. 4, 2026

Got story updates? Submit your updates here. ›

Boston Scientific Corp. forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading. The company projected 2026 adjusted earnings per share of $3.43 to $3.49, with the midpoint at $3.46 falling short of the average analyst estimate of $3.47 per share. Boston Scientific also expects organic revenue growth of 10% to 11% for 2026, marking a deceleration from the 15.8% organic growth recorded in 2025.

Why it matters

Boston Scientific's cautious guidance on future revenue and earnings growth raises concerns about the company's ability to maintain its strong performance, especially as it prepares to integrate its $14.5 billion acquisition of Penumbra. Investors will be closely watching how the company navigates this transition and whether it can deliver on its long-term growth targets.

The details

Boston Scientific reported adjusted earnings of 80 cents per share for the fourth quarter, beating the consensus estimate of 78 cents, while revenue of $5.29 billion edged past forecasts of $5.28 billion. However, the company's subdued outlook for 2026 overshadowed these strong results, with Boston Scientific projecting adjusted earnings per share of $3.43 to $3.49 and organic revenue growth of 10% to 11%, down from 15.8% in 2025.

  • Boston Scientific reported its Q4 2025 results on February 4, 2026.
  • The company provided its 2026 guidance on February 4, 2026.

The players

Boston Scientific Corp

A medical device company that develops, manufactures and markets medical devices for a variety of interventional medical specialties, including interventional cardiology, peripheral interventions, cardiac rhythm management, electrophysiology, vascular surgery, neurovascular intervention, and urology.

Penumbra

A medical device company that develops, manufactures and markets innovative products for the treatment of stroke and other vascular and neurovascular diseases.

Got photos? Submit your photos here. ›

What’s next

Investors will be closely watching Boston Scientific's integration of the Penumbra acquisition and whether the company can deliver on its long-term growth targets.

The takeaway

Boston Scientific's cautious 2026 revenue and earnings guidance, despite strong Q4 results, highlights the challenges the company faces as it seeks to maintain its growth momentum while integrating a major acquisition. Investors will be closely monitoring the company's performance in the coming year to see if it can overcome these headwinds.